Presentation is loading. Please wait.

Presentation is loading. Please wait.

the SNP profile using 26 prostate cancer GWAS risk SNPs

Published byTodd Bates Modified over 6 years ago

Similar presentations

Presentation on theme: "the SNP profile using 26 prostate cancer GWAS risk SNPs"— Presentation transcript:

1 the SNP profile using 26 prostate cancer GWAS risk SNPs
Figure 2 Predicted cumulative risk of prostate cancer for a 50-year-old male with a positive family history (father with prostate cancer), by percentile of the SNP profile using 26 prostate cancer GWAS risk SNPs Permission obtained from Wiley-Liss © MacInnes, R. J. et al. Genetic Epidemiol. 35, 549–556 (2011) Eeles, R. et al. (2013) The genetic epidemiology of prostate cancer and its clinical implications Nat. Rev. Urol. doi: /nrurol

Download ppt "the SNP profile using 26 prostate cancer GWAS risk SNPs"

Similar presentations

Tyrosine kinase signalling (review) TGF signalling Notch signalling.

Tyrosine kinase signalling (review) TGF signalling Notch signalling.
PCa Screening New Areas of Research Francesco Montorsi Milan.

PCa Screening New Areas of Research Francesco Montorsi Milan.
Evidence for Autosomal Dominant Inheritance of Prostate Cancer

Evidence for Autosomal Dominant Inheritance of Prostate Cancer
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.

Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.
Figure 4 Types of urinary diversion

Figure 4 Types of urinary diversion
Figure 1 Male infertility and assisted reproduction globally

Figure 1 Male infertility and assisted reproduction globally
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Figure 2 Recruitment of experts to the Delphi study

Figure 2 Recruitment of experts to the Delphi study
Figure 5 Types of urinary diversion

Figure 5 Types of urinary diversion
Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.
Figure 2 Multiscale modelling in oncology

Figure 2 Multiscale modelling in oncology
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 3 Birt–Hogg–Dubé (BHD) renal tumour histology

Figure 3 Birt–Hogg–Dubé (BHD) renal tumour histology
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Figure 2 Risk factors for sarcopenia

Figure 2 Risk factors for sarcopenia
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Figure 3 Semantic model of the active surveillance (AS) timeline

Figure 3 Semantic model of the active surveillance (AS) timeline
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Similar presentations

Ads by Google